Takeda Unit, U.S. Pharma See Mixed Results From IBD Drug Trials
This article was originally published in PharmAsia News
Executive Summary
Takeda Pharmaceutical's U.S. unit and Sucampo Pharmaceuticals report mixed results from a pair of Phase III studies on Sucampo's Amitiza (lubiprostone) to treat opioid-induced bowel dysfunction. One trial met goals; the other fell short. Amitiza has U.S. clearance to treat chronic idiopathic constipation, but the trials for the other indication indicated the companies need to continue a separate study not expected to yield data until later this year. If that study is successful, the drug makers expect to apply to the U.S. FDA for approval next year. (Click here for more